DNL343 for Amyotrophic Lateral Sclerosis

"This medical trial is being conducted out of several geographic locations including the California Pacific Medical Center in San Francisco, CA; HonorHealth in Scottsdale, AZ.; and the University of California at San Diego in San Diego, FL., with an additional 5 sites."

"The age range for this trial is between 18 and 80. Patients younger than the minimum age requirement can look into 44 additional studies, while those above 65 years old have 394 options to consider."

"This study is hoping to find 30 ameliorative candidates aged between 18 and 80 who are suffering from amyotrophic lateral sclerosis. The following further requirements must be met: Participants must be able to ingest the medication, female participants have either undergone sterilization or entered menopause, while male subjects in conjunction with their partners of reproductive age need to use reliable contraception methods."

"As the initial phase of clinical testing, there is limited evidence regarding DNL343's safety and efficacy. Therefore, we have rated it a 1 on our scale."

"This research endeavor, which was initially published on August 11th 2021, is actively searching for participants according to clinicaltrials.gov's records and the latest update occurred on June 6th 2022."

"Affirmative. The information on clinicaltrials.gov confirms that this medical study, which was initially posted in August 11th 2021, is actively recruiting participants across 5 sites for a total of 30 patients."